^
Association details:
| Biomarker: | CDX-2 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3
Published date:
10/01/2018
Excerpt:
We conducted a biomarker study to identify significant genes to predict efficacy of cetuximab (cet) based treatment using tumor samples from mCRC patients...LYZ and RNF43 genes were found to be significantly associated with OS (coefficients, 0.21; p = 0.013) and PFS (coefficients, -0.20; p = 0.037), respectively, in the FIRE-3 set. In the JACCRO set, high expression (log2>9.07) of CDX2 predicted a significantly longer PFS (p = 0.002).
DOI:
10.1093/annonc/mdy281.031
Trial ID:
